Valion Bio, Inc. Research and Development Expense
Valion Bio, Inc. (VBIO) reported Research and Development Expense of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Valion Bio, Inc. research and development expense for the quarter ending 2026-06-30 was $2.70M, a 312.82% increase year-over-year.
- Valion Bio, Inc. research and development expense for the quarter ending 2026-03-31 was $1.85M, a 453.43% increase year-over-year.
- Valion Bio, Inc. research and development expense for the quarter ending 2026-03-30 was $1.85M, a 453.43% increase year-over-year.
- Valion Bio, Inc. research and development expense for the quarter ending 2025-12-31 was $1.28M, a 285.29% increase year-over-year.
- Valion Bio, Inc. research and development expense for fiscal 2025 was $3.13M, a 138.46% increase from fiscal 2024.
- Valion Bio, Inc. research and development expense for fiscal 2024 was $1.31M, a 20.66% decline from fiscal 2023.
- Valion Bio, Inc. research and development expense for fiscal 2023 was $1.66M, a 4.34% decline from fiscal 2022.
- Valion Bio, Inc. research and development expense for fiscal 2022 was $1.73M, a 97.04% increase from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-14 | $4.56M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-14 | ||||
| 2026-03-30 | $1.85M 10-Q · filed 2026-05-14 | $3.14M derived: sum of 2 quarters · filed 2026-05-14 | $4.00M derived: sum of 3 quarters · filed 2026-05-14 | $4.65M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.14M derived: sum of 2 quarters · filed 2026-03-30 | $2.80M derived: sum of 3 quarters · filed 2026-08-14 | $3.13M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $858.00K 10-Q · filed 2025-11-14 | $1.51M derived: sum of 2 quarters · filed 2026-08-14 | $1.85M 10-Q · filed 2025-11-14 | $2.18M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $655.00K 10-Q · filed 2026-08-14 | $990.00K 10-Q · filed 2026-08-14 | $1.32M derived: sum of 3 quarters · filed 2026-08-14 | $1.75M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $335.00K 10-Q · filed 2026-05-14 | $668.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.09M derived: sum of 3 quarters · filed 2026-05-14 | $1.39M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $755.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.06M derived: sum of 3 quarters · filed 2026-03-30 | $1.31M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $422.00K 10-Q · filed 2025-11-14 | $724.00K derived: sum of 2 quarters · filed 2025-11-14 | $980.00K 10-Q · filed 2025-11-14 | $1.34M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $302.00K 10-Q · filed 2025-08-14 | $558.00K 10-Q · filed 2025-08-14 | $918.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.25M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $256.00K 10-Q · filed 2025-05-15 | $616.00K derived: sum of 2 quarters · filed 2025-05-15 | $953.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.42M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $360.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $697.00K derived: sum of 2 quarters · filed 2025-03-21 | $1.17M derived: sum of 3 quarters · filed 2025-03-21 | $1.66M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $337.00K 10-Q · filed 2024-11-14 | $805.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.29M 10-Q · filed 2024-11-14 | $1.73M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $468.00K 10-Q · filed 2024-08-14 | $958.00K 10-Q · filed 2024-08-14 | $1.39M derived: sum of 3 quarters · filed 2024-08-14 | $1.79M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $490.00K 10-Q · filed 2024-05-15 | $925.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.32M derived: sum of 3 quarters · filed 2024-05-15 | $1.82M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $834.00K derived: sum of 2 quarters · filed 2024-03-25 | $1.33M derived: sum of 3 quarters · filed 2024-03-25 | $1.73M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $399.00K 10-Q · filed 2023-11-14 | $896.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.29M 10-Q · filed 2023-11-14 | $1.61M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $497.00K 10-Q · filed 2023-08-14 | $898.00K 10-Q · filed 2023-08-14 | $1.21M derived: sum of 3 quarters · filed 2023-08-14 | $1.39M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $401.00K 10-Q · filed 2023-05-15 | $714.00K derived: sum of 2 quarters · filed 2023-05-15 | $889.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.08M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | $401.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $488.00K derived: sum of 2 quarters · filed 2023-03-31 | $680.00K derived: sum of 3 quarters · filed 2023-03-31 | $878.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $175.00K 10-Q · filed 2022-11-14 | $367.00K derived: sum of 2 quarters · filed 2022-11-14 | $565.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $192.00K 10-Q · filed 2022-08-15 | $390.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $198.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |